News AI returns voice to paralysed woman after 18 years A stroke survivor has been given back the ability to speak for the first time in 18 years, after a breakthrough
News Biogen trumpets data from ALS trial as FDA decision looms After a torrid couple of years, Biogen can be forgiven for making the most of new data on its tofersen drug for amyotrophic lateral sclerosis (ALS) – with an elevated status among its pipel
News AI-discovered candidates show promise in ALS Candidates slow down motor neurone death in patient samples.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
